Pacira price target lowered to $37 from $42 at RBC Capital

RBC Capital lowered the firm’s price target on Pacira to $37 from $42 but keeps an Outperform rating on the shares after its Q2 earnings beat and affirmed guidance. The company continues to execute on delivering positive Exparel numbers through the first half of the year, though focus remains squarely on ongoing patent litigation vs. eVenus, with court decision likely to come August 1st, the analyst tells investors in a research note.